Skip to main content

Incyte stock price and financials

  • INCY · Nasdaq
  • Biotechnology
  • S&P 500
$120.97−0.60%Close 13 Nov 2026
Market value
$24.67B
P/E
61.15
EV / EBITDA
29.57
Beta · 1 year
0.47
Return · 1 year
+11.7%
52-week range$89.25 — $132.60

Share price close 16 Nov 2026

+6.8%1 monthHigh $122.85Low $113.07
$112.5$115$117.5$120$122.5$125Q3 FY2026 report filed 29 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+26.9%6 monthsHigh $129.93Low $92.24
$90$100$110$120$130Q2 FY2026 report filed 28 Jul 2026Q3 FY2026 report filed 29 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+22.4%year to dateHigh $129.93Low $90.30
$90$100$110$120$130Q4 FY2025 report filed 10 Feb 2026Q1 FY2026 report filed 28 Apr 2026Q2 FY2026 report filed 28 Jul 2026Q3 FY2026 report filed 29 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+16.1%1 yearHigh $129.93Low $90.30
$90$100$110$120$130Q4 FY2025 report filed 10 Feb 2026Q1 FY2026 report filed 28 Apr 2026Q2 FY2026 report filed 28 Jul 2026Q3 FY2026 report filed 29 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+120%3 yearsHigh $129.93Low $51.18
$40$60$80$100$120$140Q4 FY2023 report filed 13 Feb 2024Q1 FY2024 report filed 30 Apr 2024Q2 FY2024 report filed 30 Jul 2024Q3 FY2024 report filed 29 Oct 2024Q4 FY2024 report filed 10 Feb 2025Q1 FY2025 report filed 29 Apr 2025Q2 FY2025 report filed 29 Jul 2025Q3 FY2025 report filed 28 Oct 2025Q4 FY2025 report filed 10 Feb 2026Q1 FY2026 report filed 28 Apr 2026Q2 FY2026 report filed 28 Jul 2026Q3 FY2026 report filed 29 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+16.7%10 yearsHigh $149.24Low $51.18
$50$75$100$125$150Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Incyte reported revenue of $5.14 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 21.2% from fiscal 2024. Net income was $1.29 billion and diluted earnings per share $6.41.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $1.56 billion, up 14.0% from a year earlier.

Figures from Incyte's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.

Against Health Care

Growth
Top quarter
Revenue +14.0% a year over five years · 6th of 37
Profitability
Top 10%
Return on invested capital 25.5%, five-year average · 3rd of 38
Balance sheet
Top 10%
More cash than debt · 2nd of 38
Valuation
Dearer than most
P/E 61.2 · 33rd of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$5.14B+21.2%
Net income
$1.29B+3845%
Diluted EPS
$6.41+4173%
Gross margin
92.8%+0.1 pts
Free cash flow
$1.35B+444%
Net cash
$3.04B

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$2B$0$2B$4B$6BRevenue, FY16: $1.11BNet income, FY16: $104.22MFY16Revenue, FY17: $1.54BNet income, FY17: −$313.14MFY17Revenue, FY18: $1.88BNet income, FY18: $109.49MFY18Revenue, FY19: $2.16BNet income, FY19: $446.91MFY19Revenue, FY20: $2.67BNet income, FY20: −$295.7MFY20Revenue, FY21: $2.99BNet income, FY21: $948.58MFY21Revenue, FY22: $3.39BNet income, FY22: $340.66MFY22Revenue, FY23: $3.7BNet income, FY23: $597.6MFY23Revenue, FY24: $4.24BNet income, FY24: $32.62MFY24Revenue, FY25: $5.14BNet income, FY25: $1.29BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 29 Oct 2026 · Full results →

Revenue
$1.56B+14.0% on a year
Gross margin
93.0%+0.3 pts on a year
Operating income
−$708.4M−260% on a year
Net income
−$784.8M−285% on a year
Diluted EPS
−$3.86−283% on a year
Free cash flow
−$691.0M−227% on a year

Comparable companies All of Health Care →

Incyte beside the other S&P 500 members in Biotechnology, by market value.

Incyte and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
IncyteINCY$24.67B−0.6%+11.7%+24.9%6.7%61.2
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0
Gilead SciencesGILD$210.2B+0.1%+36.2%+6.5%−12.5%—
BiogenBIIB$37.52B+1.2%+56.9%+2.3%3.4%108.0
ModernaMRNA—−3.4%+736%———
Regeneron PharmaceuticalsREGN—+0.4%+40.2%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-50%0%50%100%92.8%29.5%25.0%FY16FY19FY22FY25

Incyte revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By product

Incyte revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
JAKAFI$2.13B$2.41B+12.9%$2.59B+7.7%$2.79B+7.6%$3.09B+10.8%
OPZELURA$4.67M$128.7M$337.9M+162%$508.3M+50.4%$678.5M+33.5%
JAKAVI$338.0M$331.6M−1.9%$367.6M+10.9%$418.8M+13.9%$457.7M+9.3%
NIKTIMVO——$0.00$0.00$151.6M
Milestone and contract revenues$95.00M$165.0M+73.7%$7.00M−95.8%$43.00M$150.0M+249%
OLUMIANT$220.9M$134.5M−39.1%$136.1M+1.2%$135.6M−0.4%$144.6M+6.7%
MINJUVI/MONJUVI$4.91M$19.65M$37.06M+88.5%$119.2M+222%$144.6M+21.3%
ICLUSIG$109.4M$105.8M−3.3%$111.6M+5.5%$114.3M+2.4%$134.1M+17.3%
PEMAZYRE$68.53M$83.44M+21.8%$83.64M+0.2%$81.75M−2.3%$86.73M+6.1%
ZYNYZ$0.00$0.00$1.25M$3.19M$66.35M
TABRECTA$10.39M$15.41M+48.3%$17.79M+15.5%$22.75M+27.8%$26.70M+17.4%
Total revenue$2.99B$3.39B$3.70B$4.24B$5.14B

By region

Incyte revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$2.90B$3.20B+10.3%$3.51B+9.8%$3.97B+13.1%$4.80B+20.8%
Europe$124.1M$147.0M+18.5%$175.9M+19.6%$260.4M+48.1%$323.7M+24.3%
Other countries——$4.91M$6.21M+26.5%$17.57M
Total revenue$2.99B$3.39B$3.70B$4.24B$5.14B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Incyte income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$1.11B$1.54B$1.88B$2.16B$2.67B$2.99B$3.39B$3.70B$4.24B$5.14B
Revenue growth+46.7%+38.9%+22.5%+14.7%+23.5%+12.0%+13.7%+8.9%+14.8%+21.2%
Gross profit$1.05B$1.46B$1.79B$2.04B$2.54B$2.84B$3.19B$3.44B$3.93B$4.77B
Operating income$145.0M−$243.4M$129.2M$402.0M−$263.7M$585.8M$579.4M$620.5M$61.37M$1.51B
Net income$104.2M−$313.1M$109.5M$446.9M−$295.7M$948.6M$340.7M$597.6M$32.62M$1.29B
Diluted EPS$0.54−$1.53$0.51$2.05−$1.36$4.27$1.52$2.65$0.15$6.41
Gross margin94.7%94.8%95.0%94.7%95.1%94.9%93.9%93.1%92.6%92.8%
Operating margin13.1%−15.8%6.9%18.6%−9.9%19.6%17.1%16.8%1.4%29.5%
Net margin9.4%−20.4%5.8%20.7%−11.1%31.8%10.0%16.2%0.8%25.0%

Cash flow

Incyte cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$304.8M−$92.99M$336.2M$710.7M−$124.6M$749.5M$969.9M$496.5M$335.3M$1.41B
Capital expenditure$120.3M$111.0M$73.48M$78.06M$187.4M$181.0M$77.83M$32.49M$86.26M$58.87M
Free cash flow$184.5M−$204.0M$262.7M$632.6M−$312.0M$568.5M$892.1M$464.0M$249.1M$1.35B

Balance sheet and shares

Incyte balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$652.3M$899.5M$1.16B$1.83B$1.51B$2.06B$2.95B$3.21B$1.69B$3.10B
Total debt$749.8M—$19.09B$72.08M$61.72M$60.43M$55.57M$52.57M$60.34M$54.92M
Shareholders' equity$419.5M$1.63B$1.93B$2.60B$2.61B$3.77B$4.37B$5.19B$3.45B$5.17B
Diluted shares194M205M216M218M218M222M224M226M211M201M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Incyte quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.18B$1.05B$1.22B$1.37B$1.51B$1.27B$1.67B$1.56B
Revenue, year on year+16.3%+19.5%+16.5%+20.0%+27.8%+20.9%+37.7%+14.0%
Gross margin92.5%93.0%93.5%92.8%92.0%91.8%93.7%93.0%
Operating income$301.5M$205.2M$530.3M$443.5M$335.9M$301.1M$697.9M−$708.4M
Net income$201.2M$158.2M$405.0M$424.2M$299.3M$303.3M$585.6M−$784.8M
Diluted EPS$0.97$0.80$2.04$2.11$1.46$1.47$2.81−$3.86
Free cash flow$363.8M$262.9M$25.67M$544.6M$521.4M$359.2M$495.2M−$691.0M

Operating KPIs

The operating figures Incyte reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Incyte operating KPIs
KPILatestPeriodChange on a yearRecent periods
Customer A (change on a year)10%quarter to 30 Sep 2026down 4.0 points
Customer B (change on a year)7%quarter to 30 Jun 2026down 2.0 points
Customer C (change on a year)20%quarter to 30 Jun 2026unchanged
JAKAFI revenue$826.5Mquarter to 30 Sep 2026up 4.5%
OPZELURA revenue$254.9Mquarter to 30 Sep 2026up 35.6%
Product royalty revenues$191.0Mquarter to 30 Sep 2026up 11.6%
JAKAVI revenue$132.5Mquarter to 30 Sep 2026up 5.4%
NIKTIMVO revenue$67.4Mquarter to 30 Sep 2026up 47.0%
ZYNYZ revenue$58.3Mquarter to 30 Sep 2026up 157.2%
MINJUVI/MONJUVI revenue$54.6Mquarter to 30 Sep 2026up 30.1%
Milestone and contract revenues$49.8Mquarter to 30 Sep 2026up 10.7%
OLUMIANT revenue$39.1Mquarter to 30 Sep 2026up 5.2%
ICLUSIG revenue$33.5Mquarter to 30 Sep 2026down 10.8%
PEMAZYRE revenue$21.2Mquarter to 30 Sep 2026down 6.9%
TABRECTA revenue$6.8Mquarter to 30 Sep 2026up 4.9%
United States revenue$1.4Bquarter to 30 Sep 2026up 13.8%
Europe revenue$107.4Mquarter to 30 Sep 2026up 7.0%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Incyte's revenue in fiscal 2025?

$5.14 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Incyte's net income in fiscal 2025?

$1.29 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Incyte's diluted earnings per share in fiscal 2025?

$6.41 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Incyte's gross margin?

92.8% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Incyte's operating margin?

29.5% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Incyte generate in fiscal 2025?

$1.35 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Incyte's revenue come from?

In fiscal 2025, by product: JAKAFI $3.09B (60%), OPZELURA $678.5M (13%), JAKAVI $457.7M (8.9%), NIKTIMVO $151.6M (2.9%), out of $5.14B in all, as stated in its annual report.

In the terminal

Twenty years of Incyte's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans